
    
      This is a double blind, positive comparator, randomized, multicenter, parallel group study to
      assess the efficacy, safety, and tolerability of AZD3480 as monotherapy in patients with mild
      to moderate dementia of the Alzheimer's type (AD). Approximately 300 subjects will be
      randomized and divided into 2 cohorts. Actual randomization was 293 subjects.
    
  